Eleven Biotherapeutics (EBIO) Reports Q1 Loss of $0.33/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Eleven Biotherapeutics (EBIO) Reports Q1 Loss of $0.33/Share

Eleven Biotherapeutics Reports Second Quarter 2016 Financial Results and Provides Strategic Update

August 12, 2016 7:30 AM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the second quarter ended June 30, 2016 and provided a review of recent business highlights.

We look forward to closing our licensing deal with Roche, contingent upon the approval of our stockholders at our upcoming stockholder meeting, said Abbie Celniker, Ph.D., President and Chief Executive Officer of Eleven Biotherapeutics.

Recent Business Highlights and Strategic Update:

Submitted an... More